You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(2269.HK)尾盤拉昇收漲1.7% 收購輝瑞中國生產基地提升原液和製劑產能
格隆匯 03-17 16:10
格隆匯3月17日丨入選了格隆匯2021年“下注中國”十大核心潛力資產的藥明生物(2269.HK)盤中一度跌3.4%報88.15港元,尾盤有所拉昇,最終收漲1.7%報92.8港元,市值3907億港元。公司今日宣佈與輝瑞中國達成一項收購協議,將收購輝瑞中國位於杭州的先進生物藥生產基地,相關員工也將由藥明生物接收。該交易預計2021年上半年完成,將迅速提升藥明生物原液和製劑產能,滿足激增的商業化生產服務需求。此次收購的生物藥生產基地面積達五萬平方米,於2018年投入GMP生產,包括一條原液生產線和兩條製劑生產線。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account